Treatment Responses for Brain Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if a new technology, SmartMatch, can quickly identify the best medicines for brain and spinal cord tumors by testing how removed tumor tissues react to different drugs. It targets individuals with recurring central nervous system (CNS) tumors who are already scheduled for surgery at the NIH. During surgery, researchers will collect a small piece of the tumor for testing. The results, which may guide future treatment, will be shared with the patient and their doctor. Participants will also have follow-ups every six months for three years to monitor their health.
As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could shape future treatments.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on analyzing tumor samples rather than changing your treatment plan.
What prior data suggests that SmartMatch is safe for analyzing tumor samples?
Research has shown that SmartMatch is a new method for assessing how brain tumor tissues react to different drugs. In studies, SmartMatch tests small pieces of tumor tissue to determine their response to various treatments. This process aids doctors in selecting the best medicine for each specific tumor.
While there are no direct reports on the safety of SmartMatch itself, it is important to note that it only uses tissue already removed during surgery. No additional procedures are required for SmartMatch, suggesting it is a low-risk approach.
The main goal is to assist doctors in developing better treatment plans for brain cancer in the future. Participants can feel reassured that the study does not involve any new or risky procedures beyond the surgery they are already scheduled to have.12345Why are researchers excited about this trial?
Researchers are excited about SmartMatch for brain cancer because it offers a personalized approach by using molecular profiling to tailor treatments for recurrent central nervous system (CNS) tumors. Unlike standard treatments that often follow a one-size-fits-all approach, SmartMatch focuses on the unique genetic makeup of each patient's tumor. This precision can potentially lead to more effective and targeted therapies, offering hope for better outcomes in a condition where conventional options have limited success.
What evidence suggests that SmartMatch is effective for analyzing CNS tumors?
Research has shown that SmartMatch, used by participants in this trial, utilizes tumor samples to identify medicines that might work for specific brain cancers. This technology tests how small parts of a tumor react to different drugs. Early results suggest that SmartMatch can quickly identify potential treatment options, providing doctors with more information to guide care decisions. Although the results may not always be useful, this method aims to offer a personalized approach to cancer treatment. Overall, SmartMatch could provide a new way to better understand and treat brain tumors.12678
Who Is on the Research Team?
Jing Wu, M.D.
Principal Investigator
National Cancer Institute (NCI)
Are You a Good Fit for This Trial?
This study is for people aged 15 and older with recurrent brain or spinal cord tumors who are already scheduled for surgery at the NIH. They must be able to understand and consent to the study, which may include those under a guardian's care.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Surgery and Sample Collection
Tumor and blood samples are collected during planned surgery for SmartMatch analysis
SmartMatch Analysis
SmartMatch drug screen analysis is performed on tumor samples to generate a report
Follow-up
Participants are monitored remotely for health updates every 6 months for 3 years
What Are the Treatments Tested in This Trial?
Interventions
- SmartMatch
Trial Overview
The trial tests SmartMatch technology on tumor samples from surgeries to find suitable drugs for each patient's specific tumor type. The goal is to analyze these samples within 21 days post-surgery and use the findings in treatment planning.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Turnaround time for SmartMatch platform implementation and molecular profiling of recurrent CNS tumors
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor
Citations
Observational Study of Responses to Treatments in ...
The tumor samples will be sent to a lab for SmartMatch analysis. Once completed, the results will be shared with the patient and his/her local ...
Automatic smart brain tumor classification and prediction ...
This study proposes a smart monitoring system for the early and timely detection, classification, and prediction of brain tumors.
Treatment Responses for Brain Cancer · Info for Participants
SmartMatch is a new technology that tries to help find the best medicines for the particular tumor by testing how small pieces of surgically removed tumor ...
Gaps in Diagnosis, Treatment, and Outcomes Among ...
These data collectively suggest that effective treatment for brain tumors is not currently equitably accessible. Structural, financial, and institutional ...
A Systematic Review and Meta-Analysis of Brain Tumors ...
The study found that the best algorithms had a pooled lesion-wise Dice score of 84%, with pooled sensitivities of 87% (patient-wise) and 86% (lesion-wise). Post ...
Monitoring for Cancer Spread to the Central Nervous ...
If the researchers can identify the early onset of CNS metastases, they can immediately treat that cancer and possibly prevent it from worsening. Currently, ...
Smart Nanoformulations for Brain Cancer Theranostics
The aim of this review is to evaluate the suitability of novel smart nanobiotechnological approaches in brain cancer therapy.
Value of artificial intelligence in neuro-oncology
For instance, AI-based brain metastasis risk scores derived from bulk RNA-seq data have revealed metastasis-associated epithelial cells in ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.